MVVC 2 – Field trials of a new combination malaria vaccine in West African Adults and Children

Objectives

The Malaria Vectored Vaccine Consortium (MVVC) 2 builds on the established network of MVVC 1, which aims to develop a malaria vaccine candidate, while building capacity at the African clinical trial sites and driving the development of a strong network of its partners.

This project will aim to determine whether addition of a circumsporozoite protein (CSP) particle in adjuvant will enhance the efficacy of vectored prime-boost vaccines for P. falciparum.